![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan (M.K., H.Y., M.F., K.K., T.K.); Kokura Memorial Hospital, Kitakyushu, Japan (G.H.); and Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan (J.S., K.N., T.I.)
In a caffeine test previously performed with healthy Japanese volunteers, we found that the CYP1A2 index defined as urinary {5-acetylamino-6-amine-3-methyluracil (AAMU) + 1-methylxanthine (1X) + 1-methyluric acid (1U)}/1,7-dimethyluric acid (17U) was affected by the whole deleted allele of CYP2A6 (CYP2A6*4). Since the high value of the CYP1A2 index could be caused by a low urinary concentration of 17U, we postulated that CYP2A6 was responsible for the 1,7-dimethylxanthine (17X) metabolism to generate 17U (17X 8-hydroxylation). Thus, the role of CYP2A6 in the 17X 8-hydroxylation was fully examined in the present study. Among 10 isoforms of human cytochrome P450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, or CYP3A5) expressed in Escherichia coli cells, CYP2A6 and CYP1A2 showed high catalytic activities for the 17X 8-hydroxylation. The 17X 8-hydroxylase activities significantly associated with coumarin 7-hydroxylase activities (r = 0.67, p < 0.01) in liver microsomes from 17 individuals, but not with ethoxyresorufin O-deethylase activities. Tranylcypromine, an inhibitor of CYP2A6, reduced the 17X 8-hydroxylase activities of human liver microsomes. The 17X 8-hydroxylase activities of CYP2A6.7, CYP2A6.10, and CYP2A6.11 expressed in E. coli cells were 12, 13, and 22% of that of CYP2A6.1, respectively. The 17X 8-hydroxylase activities were found to be low in liver microsomes from individuals possessing the deletion or mutations in the CYP2A6 gene. Based on these data, we conclude that CYP2A6 is a main 17X 8-hydroxylase and that the catalytic activities for the 17X 8-hydroxylation are reduced by the genetic polymorphisms of the CYP2A6 gene.
This article has been cited by other articles:
![]() |
K. S. Derby, K. Cuthrell, C. Caberto, S. G. Carmella, A. A. Franke, S. S. Hecht, S. E. Murphy, and L. Le Marchand Nicotine Metabolism in Three Ethnic/Racial Groups with Different Risks of Lung Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3526 - 3535. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Sinues, A Fanlo, E Mayayo, C Carcas, J Vicente, I Arenaz, and A Cebollada CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives Human and Experimental Toxicology, May 1, 2008; 27(5): 367 - 372. [Abstract] [PDF] |
||||
![]() |
T. Endo, M. Ban, K. Hirata, A. Yamamoto, Y. Hara, and Y. Momose Involvement of CYP2A6 in the Formation of a Novel Metabolite, 3-Hydroxypilocarpine, from Pilocarpine in Human Liver Microsomes Drug Metab. Dispos., March 1, 2007; 35(3): 476 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Malaiyandi, S. D. Goodz, E. M. Sellers, and R. F. Tyndale CYP2A6 Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers during Ad libitum Smoking. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1812 - 1819. [Abstract] [Full Text] [PDF] |
||||